| http://www.w3.org/ns/prov#value | - Indeed, one of the major problems faced by anti-HBV therapy is the slow kinetics of cccDNA clearance from the infected liver using nucleoside analogs either as monotherapy[3] or in combination with pegylated interferon-alpha.[8] One study performed in chronically infected woodchucks showed the effect of long-term entecavir treatment on cccDNA clearance without selection of drug-resistant mutants.[
|
